Bruker Corp's stock fell 7.72% as it hit a 5-day low amid a broader market decline, with the Nasdaq-100 down 0.17% and the S&P 500 down 0.24%.
The company has secured two multi-year supply agreements with global radiology firms, expected to generate approximately $500 million in future revenues. These agreements, which extend up to seven years, will enhance Bruker's competitive position in the MRI magnet market by supplying high-performance superconductors to production sites in the U.S. and the U.K., supporting innovative helium-free MRI magnet architectures.
This strategic move not only solidifies Bruker's leadership in the superconducting materials sector but also aligns with the industry's focus on sustainability and cost reduction, potentially driving future growth.
Wall Street analysts forecast BRKR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BRKR is 52.18 USD with a low forecast of 40.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
Wall Street analysts forecast BRKR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BRKR is 52.18 USD with a low forecast of 40.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
4 Hold
1 Sell
Moderate Buy
Current: 46.550
Low
40.00
Averages
52.18
High
60.00
Current: 46.550
Low
40.00
Averages
52.18
High
60.00
Guggenheim
Buy
maintain
$53 -> $58
2026-01-26
New
Reason
Guggenheim
Price Target
$53 -> $58
AI Analysis
2026-01-26
New
maintain
Buy
Reason
Guggenheim raised the firm's price target on Bruker to $58 from $53 and keeps a Buy rating on the shares. The firm adjusted models, forecasts and targets for a number of its Diagnostics and Life Sciences Tools covered companies to reflect recent updates and selected pre-announcements of preliminary results last week.
Citi
Neutral
maintain
$40 -> $53
2026-01-16
Reason
Citi
Price Target
$40 -> $53
2026-01-16
maintain
Neutral
Reason
Citi raised the firm's price target on Bruker to $53 from $40 and keeps a Neutral rating on the shares. The firm adjusted targets in the life science tools and diagnostics group after meeting with companies. Commentary around pharma was positive, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BRKR
Unlock Now
TD Cowen
Hold
maintain
$42 -> $53
2026-01-07
Reason
TD Cowen
Price Target
$42 -> $53
2026-01-07
maintain
Hold
Reason
TD Cowen raised the firm's price target on Bruker to $53 from $42 and keeps a Hold rating on the shares. The firm adjusted targets in the life science tools space as part of a Q4 outlook. While the bar is higher for the Q4 results following the recent share rallies, many companies "already soft guided" 2026, the analyst tells investors in a research note. TD believes this sets room for upside in 2026.
Guggenheim
Subbu Nambi
Buy
maintain
$45 -> $53
2026-01-05
Reason
Guggenheim
Subbu Nambi
Price Target
$45 -> $53
2026-01-05
maintain
Buy
Reason
Guggenheim analyst Subbu Nambi raised the firm's price target on Bruker to $53 from $45 and keeps a Buy rating on the shares. The firm adjusted its models and forecasts for its covered Diagnostics and Life Sciences Tools companies to reflect recent updates from the companies after meetings with management teams.
About BRKR
Bruker Corporation is a developer, manufacturer and distributor of high-performance scientific instruments and analytical and diagnostic. Its segments include Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI NANO, and Bruker Energy & Supercon Technologies (BEST). BSI segment designs, manufactures and distributes life science tools based on magnetic resonance technology and offers automated laboratory research. BSI CALID segment designs, manufactures and distributes life science mass spectrometry, applied spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments and solutions. BSI NANO designs, manufactures and distributes advanced x-ray instruments, atomic force microscopy instrumentation, and fluorescence optical microscopy instruments. BEST segment develops and manufactures superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare and energy physics research.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
